Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Follicular lymphoma is considered incurable; patients often relapse, and with each relapse remission and time to next treatment shorten; transformation to DLBCL can occur in more than 25% of FL patients.

  60% confidence

• The safety profile of epcoritamab + R2 was manageable across all patient subgroups and consistent with that observed in the overall trial population, with no new safety signals identified.

  60% confidence

• Epcoritamab + R2 demonstrated PFS benefits favoring the combination with hazard ratios consistently below 0.3 across all analyzed FLIPI, POD24, and NHL-5 subgroups, indicating substantially reduced risk of disease progression or death compared to R2 alone.

  60% confidence

• The EPCORE FL-1 subgroup analysis demonstrated consistent and deep responses with a manageable safety profile across all patient characteristics, including varying risk profiles and lenalidomide dosing schedule, validating the potential of the combination therapy; epcoritamab combined with rituximab and lenalidomide is poised to transform the treatment paradigm for R/R follicular lymphoma.

  60% confidence

• The EPCORE FL-1 trial, bolstered by this subgroup analysis, established fixed-duration epcoritamab in combination with R2 for relapsed or refractory follicular lymphoma; it delivers consistent efficacy and a manageable safety profile, regardless of comorbidity burden.

  60% confidence

• Although adverse events such as neutropenia and infections were more frequent among patients receiving lower lenalidomide doses, the consistent and sustained efficacy of epcoritamab + R2 compared with R2 alone was maintained in this subgroup.

  60% confidence

Citado nestas reportagens da Via News

• FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies →
• Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →